Emergent BioSolutions Inc.EBS
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States
Emergent BioSolutions' mission is to protect and save lives. For over 25 years, the company has prepared those entrusted with protecting public health, delivering protective and life-saving solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Key ratios
Operating cash flow growth
-42.2%TTM
2025
190.6%
FCF / Sales
11.2%TTM
2025
21.1%2024
3.4%2023
-24.6%
Net margin
-23.0%TTM
2025
7.1%2024
-18.3%2023
-72.5%
ROA
6.9%TTM
2025
5.3%2024
-2.0%2023
-4.2%
ROE
-40.3%TTM
2025
10.5%2024
-33.7%2023
-74.7%
Revenue growth
-9.6%TTM
2025
-28.8%2024
-0.5%2023
-6.1%
Recent news
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
Emergent BioSolutions Completes Repurchase of $75 Million of Senior Unsecured Notes
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
Track EBS in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer